Nasonex (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to intracellular glucocorticoid receptors. This binding alters gene expression, suppressing inflammatory cytokines, decreasing vascular permeability, and limiting leukocyte infiltration, which together reduce swelling and mucus production in the nasal mucosa.

The appropriate dose of Nasonex is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and specific indication. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Nasonex in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To order Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both Nasonex (mometasone furoate) and fluticasone are intranasal corticosteroids with similar anti‑inflammatory actions. Mometasone has a slightly higher receptor affinity, which may allow effective symptom control at lower spray volumes, but clinical choice often depends on individual response, tolerability, and prescriber preference.

Nasonex should be stored at room temperature, below 25 °C (77 °F). Keep the bottle in its original packaging, protect it from moisture and direct heat, and ensure the cap is tightly closed when not in use.

Nasonex is administered as a nasal spray. The patient gently shakes the bottle, primes it if required, tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed.

Serious risks, though uncommon, include nasal septal perforation, severe or prolonged nosebleeds, adrenal suppression with prolonged high‑dose use, fungal infections of the nasal cavity, and rare systemic allergic reactions such as anaphylaxis. Patients should seek medical attention if any of these occur.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or those who have experienced severe adverse reactions to other intranasal corticosteroids.